SAN DIEGO, Oct. 26 -- Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041
The Company's flu program has identified a compound, IkT-041, comparable in activity to viral neuraminidase inhibitors (e.g. Tamiflu, Relenza), but one that is far less likely to stimulate resistance. IkT-041 has excellent human dosing metrics (up to 3000 mg/day), outstanding safety history in humans and an oral bioavailability > 70%.
The Company's orphan drug program is focused on satisfying an unmet medical need for the treatment of polyomavirus infections. The human polyomaviruses, JC and BK, are responsible for fatal disorders of the brain and kidney, to include progressive multifocal leukoencephalopathy (PML), an AIDS-defining disease that also afflicts patients on autoimmune disorder treatments for MS, lupus and arthritis. IkT-001 has a mechanism of action that can suppress polyomavirus reactivation in viral reservoirs, even in patients who are immune compromised. In some cases, a therapeutic vaccine effect can be realized with this product.
The Company is on track to file 3 Initial New Drug applications in 2010 or early 2011 and enter late stage clinical trials shortly thereafter. First product launch is slated for 2013, addressing a total market of greater than 100 million patients with annual revenue potential of at least $2.3 billion.
SOURCE Inhibikase Therapeutics
Subscribe to our Free Newsletters!
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Dizziness is a feeling of being faint or unsteady whereas Vertigo is a feeling that you or your ...View All